Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analyst

After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax's program could be destined to reap billions of dollars in sales this year, one group of analysts predicts. Chalk it up to what’s looking like a strong first-quarter revenue haul for the Gaithersburg, Maryland-based biotech, Jefferies analysts wrote in a note to clients Tuesday following a chat with Novavax’s chief financial officer Jim Kelly. The company’s only marketed product is its protein-based coronavirus vaccine Nuvaxovid, which is slowly racking up green lights in places like the EU, the U.K., Australia and South Korea.